Trial Profile
A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Nivolumab/relatlimab (Primary) ; Relatlimab (Primary)
- Indications Bladder cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms RELATIVITY-020
- Sponsors Bristol-Myers Squibb
- 06 Feb 2024 Planned End Date changed from 25 Aug 2026 to 10 Sep 2025.
- 09 Jun 2023 Planned primary completion date changed from 13 Sep 2023 to 10 Sep 2024.
- 11 Apr 2023 Planned primary completion date changed from 27 Sep 2023 to 13 Sep 2023.